×
Investigational medicinal products should be produced in accordance with the principles and the detailed guidelines of Good Manufacturing Practice for Medicinal Products. Procedures need to be flexible to provide for changes as knowledge of the process increases, and appropriate to the stage of development of the product. In clinical trials there may be added risk to participating subjects compared to patients treated with marketed products. The application of GMP to the manufacture of investigational medicinal products is intended to ensure that trial subjects are not placed at risk, and that the results of clinical trials are unaffected by inadequate safety, quality or efficacy arising from unsatisfactory manufacture. The production of investigational medicinal products involves added complexity in comparison to marketed products by virtue of the lack of fixed routines, variety of clinical trial designs, consequent packaging designs, and the need, often, for randomisation and blinding and increased risk of
Source of this document: Eudralex document ENTR/F/2/AM/an D(2010) 3374 of 3 February 2010 with full title “The Rules Governing Medicinal Products in the European Union, Volume 4, EU Guidelines to Good Manufacturing Practice, Medicinal Products for Human and Veterinary Use, Annex 13: Investigational Medicinal Products”, published by European Commission‘s Enterprise and Industry Directorate-General, © European Union, 2010.
Permission for reproduction (2010-COP-197 A 152915) granted to PharmDev Innovations GmbH by the Publications Office of the European Union. No liability is assumed for correct transscript of the official text.
Permission for reproduction (2010-COP-197 A 152915) granted to PharmDev Innovations GmbH by the Publications Office of the European Union. No liability is assumed for correct transscript of the official text.